Assess whether to resubmit, meet, or pause the program (bf549c)

SITUATION A pediatric ethicist objecting to the proposed design put biosimilar analytical similarity report in front of CMC change-control owner in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / Clinical and Evidence Strategy close is to resubmit, meet, or from biosimilar analytical similarity report, and the live options are To resubmit, meet,, Pause the program.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. The population in biosimilar analytical similarity report is the one a pediatric ethicist objecting to the proposed design named, so To resubmit, meet, follows for this Clinical and Evidence Strategy file. 2. The population in biosimilar analytical similarity report is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the program is the honest Pharma & Life Sciences call. 3. A safety team sitting on a new disproportionate signal already contained a pediatric ethicist objecting to the proposed design before biosimilar analytical similarity report arrived; no new Clinical and Evidence Strategy path. 4. Provenance on biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move to resubmit, meet, or for CMC change-control owner.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for CMC change-control owner - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Clinical and Evidence Strategy finding in biosimilar analytical similarity report that a second reviewer can re-perform - Missing page in biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design, if any